Plasma Therapy Market: Information by Type (Leukocyte-Rich PRP), Source (Autologous ), Application (Orthopedic), End-User (Research Institution), and Region — Forecast till 2029

May 27, 2020   Market Overview Plasma therapy aims at using antibodies from the blood to treat chronic, life-threatening conditions. In the last few years, plasma therapy has proven to be an effective treatment in terms of improving life expectancies and survival rates. Increasing incidences of accidental blood loss and rising healthcare expenditure provide an impetus the market growth. Plasma therapy is emerging as a standard practice, and a number of healthcare professionals are actively adopting the thera...
Request Free Sample Report

Table Of Content

TABLE OF CONTENTS

1          Introduction

1.1       Market Definition

1.2       Market Scope

2          Research Methodology

2.1       Primary Research

2.2       Research Methodology

2.3       Assumptions & Exclusions

2.4       Secondary Data Sources

3          Market Overview

3.1       Report Segmentation & Scope

3.2       Value Chain Analysis: Plasma Therapy Market

3.3       Key Market Trends

3.3.1   Drivers

3.3.2   Restraints

3.3.3   Opportunities

3.4       Porter’s Five Forces Analysis

3.4.1   Bargaining Power of Suppliers

3.4.2   Bargaining Power of Buyers

3.4.3   Threat of Substitution

3.4.4   Threat of New Entrants

3.4.5   Competitive Rivalry

3.5       Market Share Analysis

3.6       Top Wining Strategies

3.7       Top Investment Pockets

3.8       Impact of COVID 19

4          Type Overview

4.1       Introduction

4.1.1   Market Size & Forecast (Value)

4.2       Pure Platelet-Rich Plasma (PRP)

4.2.1   Market Size & Forecast (Value)

4.3       Leucocyte-Rich PRP

4.3.1   Market Size & Forecast (Value)

4.4       Pure Platelet-Rich Fibrin (PRF)

4.4.1   Market Size & Forecast (Value)

4.5       Leucocyte Rich Fibrin (L-PRF)

4.5.1   Market Size & Forecast (Value)

4.6       Plasma Proteins

4.6.1   Market Size & Forecast (Value)

4.7       Others

4.7.1   Market Size & Forecast (Value)

5          Source Overview

5.1       Introduction

5.1.1   Market Size & Forecast (Value)

5.2       Autologous

5.2.1   Market Size & Forecast (Value)

5.3       Allogenic

5.3.1   Market Size & Forecast (Value)

6          Applications Overview

6.1       Introduction

6.1.1   Market Size & Forecast (Value)

6.2       Orthopedics

6.2.1   Market Size & Forecast (Value)

6.3       Chronic Infectious Diseases

6.3.1   Market Size & Forecast (Value)

6.4       Dermatology

6.4.1   Market Size & Forecast (Value)

6.5       Dental

6.5.1   Market Size & Forecast (Value)

6.6       Cardiology

6.6.1   Market Size & Forecast (Value)

6.7       Others

6.7.1   Market Size & Forecast (Value)

7          End-User Overview

7.1       Introduction

7.1.1   Market Size & Forecast (Value)

7.2       Hospitals and Clinics

7.2.1   Market Size & Forecast (Value)

7.3       Research institutions.

7.3.1   Market Size & Forecast (Value)

8          Regional Overview

8.1      Introduction

8.1.1   Market Size & Forecast (Value)

8.2      America

8.2.1   North America

8.2.1.1      The U.S.

8.2.1.1.1         By Type

8.2.1.1.2         By Source

8.2.1.2      Canada

8.2.1.2.1         By Type

8.2.1.2.2         By Source

8.2.1.3      Mexico

8.2.1.3.1         By Type

8.2.1.3.2         By Source

8.2.2   Central and South America and the Caribbean

8.2.2.1      By Type

8.2.2.2      By Source

8.2.2.2.1   Brazil

8.2.2.2.1.1      By Type

8.2.2.2.1.2      By Source

8.2.2.2.2   Argentina

8.2.2.2.2.1      By Type

8.2.2.2.2.2      By Source

8.2.2.2.3   The Rest of Central and South America and the Caribbean

8.2.2.2.3.1      By Type

8.2.2.2.3.2      By Source

8.3      Europe

8.3.1   Market Size & Forecast (Value)

8.3.2   Western Europe

8.3.2.1      The U.K.

8.3.2.1.1         By Type

8.3.2.1.2         By Source

8.3.2.2      Germany

8.3.2.2.1         By Type

8.3.2.2.2         By Source

8.3.2.3      France

8.3.2.3.1         By Type

8.3.2.3.2         By Source

8.3.2.4      Spain

8.3.2.4.1         By Type

8.3.2.4.2         By Source

8.3.2.5      Italy

8.3.2.5.1         By Type

8.3.2.5.2         By Source

8.3.2.6      The Rest of Western Europe

8.3.2.6.1         By Type

8.3.2.6.2         By Source

8.3.3   Eastern Europe

8.3.3.1             By Type

8.3.3.2             By Source

8.3.4   The Rest of Europe

8.3.4.1             By Type

8.3.4.2             By Source

8.4      Asia-Pacific

8.4.1   Market Size & Forecast (Value)

8.4.2   Japan

8.4.2.1            By Type

8.4.2.2            By Source

8.4.3   China

8.4.3.1            By Type

8.4.3.2            By Source

8.4.4   Australia

8.4.4.1            By Type

8.4.4.2            By Source

8.4.5   India

8.4.5.1            By Type

8.4.5.2            By Source

8.4.6   South Korea

8.4.6.1            By Type

8.4.6.2            By Source

8.4.7   The Rest of Asia-Pacific

8.4.7.1            By Type

8.4.7.2            By Source

8.5      The Middle East & Africa

8.5.1   The Middle East

8.5.1.1            Market Size & Forecast (Value)

8.5.1.2            Saudi Arabia

8.5.1.2.1         By Type

8.5.1.2.2         By Source

8.5.1.3            The UAE

8.5.1.3.1         By Type

8.5.1.3.2         By Source

8.5.1.4            Qatar

8.5.1.4.1         By Type

8.5.1.4.2         By Source

8.5.2   The Africa

8.5.2.1            Market Size & Forecast (Value)

9          Company Profile

9.1      BioLife Plasma Services

9.1.1   Company Overview

9.1.2   Financial Performance

9.1.3   Recent Developments

9.1.4   Type Portfolio

9.2      Grifols International S.A.

9.2.1   Company Overview

9.2.2   Financial Performance

9.2.3   Recent Developments

9.2.4   Type Portfolio

9.3      Biotest

9.3.1   Company Overview

9.3.2   Financial Performance

9.3.3   Recent Developments

9.3.4   Type Portfolio

9.4      CSL Ltd.

9.4.1   Company Overview

9.4.2   Financial Performance

9.4.3   Recent Developments

9.4.4   Type Portfolio

9.5      Cambryn Biologics LLC

9.5.1   Company Overview

9.5.2   Financial Performance

9.5.3   Recent Developments

9.5.4   Type Portfolio

9.6      Bio Products Laboratory Ltd.

9.6.1   Company Overview

9.6.2   Financial Performance

9.6.3   Recent Developments

9.6.4   Type Portfolio

9.7      China Biologic Products, Inc.

9.7.1   Company Overview

9.7.2   Financial Performance

9.7.3   Recent Developments

9.7.4   Type Portfolio

9.8      Kedrion S.p.A

9.8.1   Company Overview

9.8.2   Financial Performance

9.8.3   Recent Developments

9.8.4   Type Portfolio

9.9      LFB biopharmaceutical

9.9.1   Company Overview

9.9.2   Financial Performance

9.9.3   Recent Developments

9.9.4   Type Portfolio

10             Conclusion & Recommendations

11            Acronyms & Abbreviations